BRAF inhibitors (BRAFi) combined with MEK inhibitors are standard therapy in patients with BRAF V600 mutated metastatic melanoma ([@bib15]; [@bib16]). Although highly effective, radiation therapy may still be indicated, e.g., for the treatment of brain or symptomatic bone metastases ([@bib17]; [@bib12]; [@bib20]). A recent analysis showed an increased frequency of adverse events when BRAFi were administered concomitantly with radiotherapy ([@bib10]), which subsequently lead to a drug safety warning by the FDA and other institutions. However, an interruption of BRAFi treatment may lead to decreased tumour control with the progression of non-irradiated metastases. Furthermore, in preclinical models BRAFi sensitised melanoma cells to radiotherapy ([@bib23]; [@bib5]). This radiosensitising effect could improve efficacy with improved tumour control in patients treated concomitantly. Currently, no standard approach with regard to a possible interruption of BRAFi therapy during radiotherapy exists. As this question frequently appears in clinical practice, the aim of this study is to provide reliable data on local and systemic tumour control to help decide which is more beneficial: concomitant or interrupted BRAFi treatment during radiotherapy.

Material and methods
====================

Patients
--------

Between September 2010 and January 2017 a total of 155 patients with metastatic BRAF-mutated melanoma from 17 skin cancer centres in Germany, Austria and Switzerland were retrospectively analysed. This retrospective study was approved by the local institutional review board of the Friedrich-Alexander-Universität Erlangen-Nürnberg (nr. 358_17 Bc). Informed consent was waived since only data from standard clinical therapy were collected and analysed anonymously. All patients received conventional or stereotactic radiotherapy either with concomitant or interrupted BRAFi therapy. Analyses were performed for the entire patient cohort and for vemurafenib- and dabrafenib-treated patients separately, since retrospective analyses suggest vemurafenib to be a more effective radiosensitiser than dabrafenib ([@bib10]). Kaplan--Meier analyses for local tumour control (LC), progression free survival (PFS) and overall survival (OS~RT~) were performed from the beginning of radiotherapy. In addition, OS was analysed from the beginning of the BRAFi therapy (OS~BRAFi~). If patients received more than one series of radiotherapy treatment, the first radiotherapy was selected for all analyses. Patients' characteristics are shown in [Table 1](#tbl1){ref-type="table"}. Median follow-up time was 8.1 months (range 0.1--51.4 months). During the follow-up 154 OS and 171 PFS events occurred. Toxicity was graded according CTCAE 4.0.

Statistical analysis
--------------------

Data analysis was carried out using SPSS 21.0 (IBM Corporation, Armonk, NY, USA). Patients' characteristics were checked for differences with Fisher's exact test (categorical items) and Student's *t*-test (continuous items). The Kaplan--Meier method and the log-rank test were used to analyse tumour control and survival. Univariate and multivariate regression analyses of OS were performed using Cox's proportional hazard model. Variables associated with a *P*-value \<0.35 in univariate analyses were considered for inclusion in multivariate analyses. The proportional hazard assumption was tested through plotting logminus-log curves. Toxicity in the subgroups was compared with the Mann--Whitney U test. A *P*-value below 0.05 was considered to be statistically significant.

Results
=======

Tumour control and survival of the entire patient cohort and the subgroups
--------------------------------------------------------------------------

Survival of patients receiving concomitant BRAFi therapy and radiotherapy was compared to those with interrupted BRAFi therapy during radiotherapy. All analyses were performed for the entire patient cohort with 155 patients and for patients treated with vemurafenib and dabrafenib separately. Patients' characteristics are shown in [Table 1](#tbl1){ref-type="table"} and are balanced with respect to important prognostic parameters like frequency of brain metastases (*P*=0.867). ECOG was significantly better in the interrupted group than in the concomitant group (*P*=0.003), whereas lactate dehydrogenase (LDH) tended to be more frequently increased in the concomitant group, but the latter reached no statistical significance (*P*=0.140). There were no differences in the number of pretreatments (*P*=0.145). Concomitant MEK inhibitor treatment was rare and balanced between the groups (*P*=1.000).

The starting point for the calculation of LC, PFS and OS~RT~ was the start of radiotherapy and for OS~BRAFi~ the initiation of BRAFi therapy. For the entire patient cohort the median OS~RT~ tended to be longer in the interrupted group than in the concomitant group with 9.8 months *vs* 7.3 months, respectively (*P*=0.075, [Figure 1A](#fig1){ref-type="fig"}). The median PFS was significantly longer in the interrupted group with 5.8 months *vs* 4.2 months, respectively (*P*=0.046, [Figure 1B](#fig1){ref-type="fig"}). There was no difference in median LC of the irradiated area (*P*=0.619, [Figure 1C](#fig1){ref-type="fig"}). Similarly, there was no difference when the beginning of BRAF inhibitor treatment was used for the calculation (OS~BRAFi~ interrupted 12.6 months *vs* concomitant 11.5 months, *P*=0.217, [Figure 2A](#fig2){ref-type="fig"}).

To determine potential differences between both BRAFi, interrupted and concomitant treatment with vemurafenib and dabrafenib were analysed separately. Median OS~RT~ and PFS were clearly longer in the subgroup of interrupted vemurafenib with 10.1 and 7.3 months, respectively, compared to 6.6 and 3.9 months in the subgroup of concomitant vemurafenib (*P*=0.004/*P*=0.002; [Figure 1D and E](#fig1){ref-type="fig"}, [Supplementary Tables S1 And S2](#sup1){ref-type="supplementary-material"}). OS~RT~ and PFS did not significantly differ in the subgroup of interrupted dabrafenib with 7.7 and 3.3 months, respectively, compared to concomitant treatment with 9.9 and 5.1 months (*P*=0.132/*P*=0.114). Moreover, interrupted vemurafenib treatment led to a distinctly longer OS~RT~ and PFS than interrupted dabrafenib treatment (*P*=0.022/*P*=0.004), but not than concomitant dabrafenib treatment (*P*=0.697/*P*=0.284). There was no difference in any of the subgroups for local tumour control ([Figure 1F](#fig1){ref-type="fig"}).

The mean pre-treatment period with BRAFi prior to radiotherapy was 4.2 months in the concomitant group and 2.9 months in the interrupted group. Though, the pre-treatment was 1.2 months longer in the concomitant group than in the interrupted group. It might cause a bias and therefore survival was analysed from the beginning of BRAFi treatment. In this calculation, OS also tended to be longer in the interrupted vemurafenib group than in the concomitant group (OS~BRAFi~ interrupted 13.1 months *vs* concomitant 10.9 months, *P*=0.067, [Figure 2B](#fig2){ref-type="fig"}). In conclusion, the survival benefit in the entire patient cohort showed a longer OS in the interrupted vemurafenib subgroup compared to the concomitant vemurafenib subgroup.

In a univariate analysis of the vemurafenib subgroup the effect of interrupted *vs* concomitant vemurafenib was compared to other prognostic parameters of metastatic melanoma ([Table 2](#tbl2){ref-type="table"}). In this cohort ECOG performance status, brain metastases and the duration of BRAFi pretreatment had only low impact on survival. The stronger prognostic parameters (all *P*\<0.35) as elevated LDH, radiation-associated toxicity, systemic pretreatment and interrupted vemurafenib treatment were included in a multivariate analysis. Here toxicity was the weakest variable. Systemic pretreatment (HR 1.65, 0.96--2.87, *P*=0.073) and elevated LDH (HR 1.70, 95% CI 0.96--3.00, *P*=0.070) were predictors for bad prognosis. The only independent prognostic parameter for overall survival in the multivariate analysis was interrupted *vs* concomitant treatment with vemurafenib during radiotherapy (HR 0.51, 0.29--0.88, *P*=0.015).

Furthermore, survival with respect to LDH and systemic pretreatment were analysed ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). In the subgroup of patients with elevated LDH, the OS~RT~ was longer in the interrupted vemurafenib group compared to the concomitant treatment group (*P*=0.004). In the subgroup with normal LDH this was only a trend (*P*=0.115). Especially patients with no systemic therapy prior to vemurafenib benefited from the interruption of vemurafenib during radiotherapy (*P*=0.004). In pretreated patients this effect almost disappeared (*P*=0.325). ECOG performance status had no relevant influence on OS in the entire patient cohort ([Table 2](#tbl2){ref-type="table"}).

Except for one centre, all centres had a standard procedure to either interrupt or not BRAFi therapy thus limiting potential bias for concomitant therapy in patients with a high rate of progression. An analysis conducted with the exclusion of patients with non-standard treatment and the centre without standard procedure ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}) confirmed the OS~RT~ benefit of interrupted BRAFi in the entire patient cohort (*P*=0.016) and in the vemurafenib subgroup (*P*=0.001; [Supplementary Figure S2](#sup1){ref-type="supplementary-material"}).

Safety of concomitant BRAF inhibitor therapy and radiotherapy
-------------------------------------------------------------

Since a radiosensitising effect of BRAF inhibitors has been described previously toxicity was analysed separately for both drugs and for interrupted and concomitant therapy schemes ([Table 3](#tbl3){ref-type="table"}). The median duration of BRAFi treatment interruption prior to beginning of radiotherapy was 4 days (range 0--37 days) and lasted for 17 days (range 3--68 days). Skin toxicity grade ≥2 was significantly increased in patients with concomitant vemurafenib compared to the interrupted vemurafenib group with 35% and 14% of patients, respectively, experiencing radiodermatitis (*P*=0.002). The risk of radiation dermatitis grade ≥2 tended to be lower in the group of concomitant dabrafenib treatment with 21% compared to 35% in the group of concomitant vemurafenib treatment, but without statistical significance (*P*=0.185). Follicular cystic proliferation of the irradiated skin exclusively occurred in patients with concomitant vemurafenib therapy.

Discussion
==========

Currently, no standard approach exists in clinical routine with regard to continuation or interruption of BRAFi therapy during radiotherapy. A clinically relevant radiosensitisation by BRAFi has been described and even led to a recommendation of the Eastern Cooperative Oncology Group to interrupt BRAFi treatment during radiotherapy ([@bib10]; [@bib1]). This radiosensitising effect could potentially also increase the response of the tumour cells to radiotherapy and thus improve tumour control. *In vitro* vemurafenib sensitises melanoma cells to radiotherapy ([@bib23]; [@bib5]). This large multicentre study was conducted to evaluate whether this effect also appears in melanoma patients and subsequently bases the decision on BRAFi interruption on *in vivo* data. We provide evidence that LC was equal in the BRAFi interrupted and BRAFi concomitant groups. More importantly, OS and PFS in patients taking vemurafenib were longer in the interrupted group than in the concomitant group. Thus, this study indicates that vemurafenib should be interrupted during radiotherapy, which increases efficacy and decreases toxicity. In patients taking dabrafenib OS and PFS did not differ in the interrupted and concomitant group. The lack of difference in efficacy might be attributable to the lower number of patients in the dabrafenib group. Consequently, the relevance of a treatment interruption in dabrafenib treated patients is not clear.

A limitation of this work is its retrospective design possibly resulting in unbalanced patient subgroups. However, the most important prognostic factor, the frequency of brain metastases, was equal in the subgroups. The number of patients with increased LDH tended to be higher in the concomitant group, but a subgroup analysis in patients with low and high LDH confirmed the benefit of interrupted vemurafenib in both groups. Currently, standard of therapy is combination therapy with BRAF and MEK inhibitors ([@bib15]; [@bib16]), whereas in this study cohort only few patients had additional MEK inhibitors and they were evenly distributed across groups. In both groups the frequency of irradiated anatomic locations was similar. Despite the significantly worse ECOG score of patients in the concomitant group the univariate analysis of the vemurafenib subgroup showed ECOG only as a very weak prognostic parameter in this patient cohort. In the multivariate analysis, only the interruption of vemurafenib had significant impact on OS. One bias of this retrospective analysis might have been the clinical strategy to continue BRAFi treatment in patients with high tumour burden. In an additional analysis of patients exclusively treated according to the centres' standard procedure, the survival benefit of interruption of vemurafenib during radiotherapy was confirmed. The mean pre-treatment with BRAFi was 1.2 months longer in the concomitant group than in the interrupted group. Starting the analyses from the first irradiation, this could bias the results. Possibly more patients had already progressed at the time point of radiotherapy in the concomitant group. However, when survival was calculated from the beginning of BRAFi treatment, OS also tended to be longer in the interrupted vemurafenib group than in the concomitant group. Thus, patients with interrupted vemurafenib therapy during radiotherapy really seem to have an improved OS.

As local tumour control is similar and no severe toxicities appeared, the treatment interruption of vemurafenib has probably a positive effect on systemic tumour control. This finding is in line with reports of successful re-challenge with BRAFi after treatment interruption due to acquired resistance ([@bib25]; [@bib13]; [@bib18]; [@bib22]). Additionally, immunological mechanisms could be the reason for the favorable effect of vemurafenib interruption. Since vemurafenib binds less specifically to mutated BRAF than dabrafenib and binding to wildtype BRAF ([@bib19]) could inhibit ERK activation in immune cells. This signalling pathway is essential for proliferation or maturation of several immune cells ([@bib7]; [@bib21]). Radiation therapy also changes the tumour cell phenotype and the tumour microenvironment, enhancing an anti- tumour immune response ([@bib2]). In combination with immune stimulating agents such as ipilimumab this can lead to an abscopal effect with improved tumour control distant from the irradiated metastasis ([@bib8]; [@bib3]). Similarly, vemurafenib might interact with radiation therapy immunologically ([@bib24]).

So far, it has not been proven that a treatment interruption of BRAFi prevents radiation-induced adverse events. In this patient cohort the median planned interruption of BRAFi was 4 days prior to beginning of radiation therapy and lasted for 17 days. This interruption of vemurafenib significantly reduced skin toxicity with similar if not enhanced efficacy compared to concomitant treatment. Since vemurafenib has a half-life of ∼57 h ([@bib26]), the median interruption period of vemurafenib prior to radiotherapy was approximately two half-life times. Based on our findings with regard to efficacy and safety, we recommend interrupting vemurafenib ∼4 days prior to the first irradiation.

Although toxicity in the concomitant treatment arm was increased, it was manageable in all cases. There appeared no severe visceral or even lethal complications as described in single case reports ([@bib1]). Radiation recall dermatitis has been reported previously with BRAFi ([@bib4]; [@bib6]; [@bib11]) but is rare. Consequently, BRAFi interruption after the last fraction of radiotherapy seems not necessary. Follicular cystic proliferation or the cutis verticis gyrate-like skin reaction as its maximal form appeared in 17% patients taking vemurafenib concomitantly, which is in line with other reported cases ([@bib9]; [@bib14]).

Conclusion
==========

In this retrospective multicentre study investigating a large patient cohort with metastatic melanoma treated with BRAFi therapy during radiotherapy the concomitant BRAFi therapy did not improve local or distant tumour control. Survival in patients with interrupted vemurafenib was better than in patients with concomitant treatment. The interruption of vemurafenib therapy during radiotherapy reduced the risk of radiation dermatitis. Thus, it is recommended to interrupt vemurafenib during radiotherapy. Due to lower number of patients, the relevance of treatment interruption in dabrafenib treated patients should be further investigated.
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![**Kaplan--Meier estimates of OS~RT~, PFS and LC calculated from the beginning of radiotherapy.** Overall survival (OS~RT~), progression-free survival (PFS) and local tumour control of the irradiated area (LC) were calculated from start of the first radiotherapy. The patient cohort with concomitant BRAF inhibitor and radiotherapy (RT w BRAFi) was compared to the cohort with radiotherapy and interrupted BRAF inhibitor (RT w/o BRAFi). OS~RT~, PFS and LC were calculated for concomitant and interrupted BRAF inhibitor treatment during radiotherapy (**A**, **B**, **C**) and for the subgroups treated with vemurafenib and dabrafenib (**D**, **E**, **F**). BRAFi=BRAF inhibitor; RT=radiotherapy.](bjc2017489f1){#fig1}

![**Kaplan--Meier estimates of OS~BRAFi~ calculated from the beginning of BRAFi therapy.** Overall survival (OS~BRAFi~) was calculated from start of BRAFi therapy and was analysed for patients with concomitant and interrupted BRAFi treatment during radiotherapy (**A**) and separately for the subgroups treated with vemurafenib and dabrafenib (**B**). BRAFi=BRAF inhibitor; RT=radiotherapy.](bjc2017489f2){#fig2}

###### Clinical characteristics of the patient cohort

                                           **All patients**   **Vemurafenib**  **Dabrafenib**                                                                       
  --------------------------------------- ------------------ ----------------- ---------------- ------------- ------------- ----------- ------------- ------------- -----------
  Number of patients                              87                68                               59            51                        28            17        
  Mean age in years (range)                  53 (19--85)        59 (18--83)    *P*=0.022         56 (19--85)   58 (18--83)  *P*=0.683    48 (19--73)   63 (40--80)  *P*=0.001
  Male                                         53 (61%)          43 (63%)      *P*=0.868          37 (63%)      30 (59%)    *P*=0.699     16 (57%)      13 (76%)    *P*=0.219
  Pts. with brain metastases                   54 (62%)          44 (65%)      *P*=0.867          38 (64%)      32 (63%)    *P*=1.000     16 (57%)      12 (71%)    *P*=0.528
  Concomitant MEK-inhibitor                     8 (9%)            7 (10%)      *P*=1.000              0          4 (8%)     *P*=0.043      8 (29%)       3 (18%)    *P*=0.493
  LDH                                                                          *P*=0.213                                    *P*=0.140                               *P*=0.710
   Elevated (\>250 U l^−1^)                    42 (48%)          23 (34%)                         35 (59%)      20 (39%)                   7 (25%)       3 (18%)     
   Normal (⩽250 U l^−1^)                       31 (36%)          34 (50%)                         18 (31%)      20 (39%)                  16 (57%)      11 (65%)     
   Unknown                                     14 (16%)          11 (16%)                          6 (10%)      11 (22%)                   5 (18%)       3 (18%)     
  Number of pretreatments                                                      *P*=0.145                                    *P*=0.161                               *P*=0.589
   0                                           51 (59%)          41 (60%)                         37 (63%)      31 (61%)                  14 (50%)      10 (59%)     
   1                                           25 (29%)          19 (28%)                         15 (25%)      15 (29%)                  10 (36%)       4 (24%)     
   ≥2                                          11 (13%)           2 (3%)                           7 (12%)       1 (2%)                    4 (14%)       1 (6%)      
   Unknown                                        0               6 (9%)                              0          4 (8%)                       0          2 (12%)     
  ECOG                                                                         *P*=0.003                                    *P*=0.008                               *P*=0.321
   0                                           18 (21%)          31 (46%)                         10 (17%)      22 (43%)                   8 (29%)       9 (53%)     
   1                                           28 (32%)          15 (22%)                         19 (32%)      12 (24%)                   9 (32%)       3 (18%)     
   ≥2                                          11(13%)            5 (7%)                           8 (14%)       2 (4%)                    3 (11%)       3 (18%)     
   Unknown                                     30 (34%)          17 (25%)                         22 (37%)      15 (29%)                   8 (29%)       2 (12%)     
  Irradiated sites                                                             *P*=0.757                                    *P*=0.753                               *P*=0.750
  Whole-brain radiotherapy (WBRT)              31 (36%)          28 (41%)                         24 (41%)      23 (45%)                   7 (25%)       5 (29%)     
  Stereotactic radiotherapy (STX) brain        23 (26%)          16 (24%)                         14 (24%)       9 (18%)                   9 (32%)       7 (41%)     
  Bone metastases                              14 (16%)           8 (12%)                          9 (15%)       7 (14%)                   5 (18%)       1 (6%)      
  Axillary lymph nodes                          7 (8%)            7 (10%)                          3 (5%)        6 (12%)                   4 (14%)       1 (6%)      
  Mediastinal metastases                        5 (6%)            1 (1%)                           4 (7%)        1 (2%)                    1 (4%)           0        
  Soft tissue metastases                        4 (5%)            5 (7%)                           3 (5%)        3 (6%)                    1 (4%)        2 (12%)     
  Others                                        3 (3%)            3 (4%)                           2 (3%)        2 (4%)                    1 (4%)        1 (6%)      

Abbreviations: ECOG=Eastern Cooperative Oncology Group; LDH=lactate dehydrogenase.

###### Univariate and multivariate analysis of the vemurafenib subgroup

                                                                  **Univariate analysis**    **Multivariate analysis**                                 
  --------------------------------------------------------------- ------------------------- --------------------------- ------- ------- -------------- -----------
  ECOG (0 (*n*=29) *vs* \>0 (*n*=38))                             1.007                            0.505--2.006         0.985     ---        ---           ---
  LDH (⩽ 250 (*n*=26) v.\>250 U/l (*n*=41))                       1.514                            0.805--2.849         0.199    1.698   0.959--3.008     0.070
  Brain metastases (no (*n*=26) *vs* yes (*n*=41))                1.194                             0.637--2.24         0.580     ---        ---           ---
  Period BRAFi RT (⩽58 days (*n*=37) *vs*\>58 days (*n*=30))      1.155                            0.668--1.999         0.606     ---        ---           ---
  Toxicity (no (*n*=33) *vs* any (*n*=34))                        1.656                            0.622--4.407         0.312    1.455   0.635--3.334     0.376
  Drugs (only BRAFi (*n*=30) *vs* drug prior to BRAFi (*n*=37))   1.746                            0.991--3.077         0.054    1.654   0.955--2.866     0.073
  Vemurafenib (concomitant (*n*=36) *vs* interrupted (*n*=31))    0.683                            0.309--1.512         0.347    0.507   0.293--0.877   **0.015**

Abbreviations: BRAFi=BRAF inhibitor; CI=confidence interval; ECOG=Eastern Cooperative Oncology Group; LDH=lactate dehydrogenase.

Variables associated with a *P*-value \<0.35 in univariate analyses were considered for inclusion in multivariate analyses. *P*-values \<0.05 were considered to be statistically significant and were marked in bold.

###### Adverse events of patients treated with BRAF inhibitor in combination with radiotherapy

                                          **Concomitant vemurafenib (*n*=59)**   **Interrupted vemurafenib (*n*=51)**   **Concomitant dabrafenib (*n*=28)**   **Interrupted dabrafenib (*n*=17)**
  -------------------------------------- -------------------------------------- -------------------------------------- ------------------------------------- -------------------------------------
  **Radiation dermatitis**                                                                                                                                   
   1°                                                   11 (19%)                               6 (12%)                                4 (14%)                               2 (12%)
   2°                                                   15 (25%)                               6 (12%)                                4 (14%)                                  0
   3°                                                   6 (10%)                                 1 (2%)                                2 (7%)                                   0
  **Other adverse events**                                                                                                                                   
  Follicular cystic proliferation         10 (17%)[a](#t3-fn2){ref-type="fn"}                     0                                      0                                     0
  Hearing disorder                                       4 (7%)                                   0                                      0                                     0
  Dysphagia                                              2 (3%)                                   0                                      0                                     0
  Hyperpigmentation                                      1 (2%)                                 3 (6%)                                   0                                     0
  Impaired wound healing                                 1 (2%)                                   0                                   1 (4%)                                   0
  Haemorrhagic intracranial metastasis                   1 (2%)                                   0                                   1 (4%)                                   0
  Pneumonitis                                            1 (2%)                                   0                                   1 (4%)                                   0
  Others[a](#t3-fn2){ref-type="fn"}        3 (5%)[b](#t3-fn3){ref-type="fn"}      1 (2%)[c](#t3-fn4){ref-type="fn"}                      0                     1 (6%)[d](#t3-fn5){ref-type="fn"}

Adverse events appearing in more than one patient in the entire cohort are listed in the table while adverse events occurring in only one patient are summarised in 'Others'.

Includes one case of cutis verticis gyrate-like toxicity as the maximal form of follicular cystic proliferation.

One case each of cardiac insufficiency, hand-food syndrome and taste disorder

Radiation recall dermatitis

Pruritus.
